Orchestra Biomed Holdings Inc

This proposal asks stockholders to approve the Orchestra BioMed 2026 Employee Stock Purchase Plan, which would reserve up to 750,000 shares (approximately 1.25% overhang at the record date) to enable eligible employees to acquire company stock through payroll deductions under a Section 423-qualified component for U.S. employees and a parallel Non-423 component to permit participation by non-U.S. employees. Management seeks shareholder approval to implement a broad-based incentive intended to retain employees, increase employee ownership and align employee interests with long-term shareholder value; the Compensation Committee relied on advice from independent consultant FW Cook and considered dilution and benchmarking in recommending the plan. The plan includes customary features: offering and purchase periods of up to 27 months, purchase price set at the lesser of 85% of the fair market value at offering or purchase date, eligibility and per-participant limits (including a $25,000 annual limitation under Section 423), discretionary holding period up to one year, and anti-dilution and corporate-transaction adjustment provisions. From a governance perspective, the requested share reserve is modest relative to total outstanding shares and the Board’s calculation of overhang (about 1.25%) suggests limited immediate dilution; the plan also contemplates Form S-8 registration and Board discretion over many design elements that could affect future dilution and foreign participation. Potential shareholder concerns include expansion of the equity pool over time, the Board’s broad administrative discretion (including ability to set offering terms and exclude certain employees), and the Non-423 component which may permit terms differing from the Section 423 tax-qualified features for foreign participants. Overall, the Board frames the ESPP as a routine and broadly accepted compensation and retention mechanism for growth-stage life sciences companies; because the share reserve is relatively small and the plan includes standard protections and limits, the Board recommends a ‘‘For’’ vote while noting that stockholders will retain oversight through future equity plan approvals and disclosure. The voting standard is a majority of shares present and entitled to vote; broker non-votes will not count toward approval. The plan’s implementation will increase employee ownership and may modestly dilute existing holders over time, but management argues the long-term benefits of retention and alignment with company performance justify approval.

This management-sponsored, non-binding say-on-pay proposal asks stockholders to endorse the compensation paid to the Company’s Named Executive Officers as disclosed in the proxy statement. Management seeks this advisory approval as a governance and accountability measure to validate its mix of fixed pay, performance-based cash bonuses tied to corporate goals and stretch goals, and equity awards (including RSUs and stock options) designed to retain executives and align their long-term interests with shareholders. The Compensation Committee engaged FW Cook as an independent compensation consultant, used a peer group benchmark, and linked bonuses to program-specific operational milestones (e.g., BACKBEAT study enrollment, Virtue SAB progress and financial objectives), which the committee says supports pay-for-performance alignment; for 2025 the committee applied metrics and stretch-goals and awarded bonuses above target reflecting measured achievements. However, sophisticated investors will note that much of the realized compensation value is equity-based and dependent on future share-price appreciation and vesting, while the company remains pre-commercial and reported net losses, which complicates a pure pay-for-TSR assessment; the Pay Versus Performance disclosure highlights the relationship between compensation actually paid and net loss/TSR over the covered periods. The Board recommends a ‘‘For’’ vote and will consider the advisory outcome in future compensation decisions, but the vote is non-binding; investors may weigh the appropriateness of incentive metrics, the level of realized pay (including one-time grants and special awards), severance and change-in-control provisions, and the use of discretionary adjustments in bonus determinations. In context, the company has used discretionary elements (e.g., midyear adjustments, modifiers for the CFO) and special one-time grants in 2025 that increased compensation levels; the Compensation Committee defends this as necessary to retain key talent and to incentivize achievement of challenging clinical and financing milestones. For governance-conscious investors, the key considerations are whether the disclosed plan and its implementation create the right incentives for long-term value creation, whether pay outcomes reflect verifiable performance, and whether equity dilution remains within acceptable limits; the Board’s recommendation and continued engagement with shareholders indicate responsiveness to shareholder views.

This advisory management proposal asks shareholders to indicate their preference for how frequently the non-binding say-on-pay advisory vote should be held—every 1, 2, or 3 years. The Board and Compensation Committee recommend an annual (1-year) frequency on the grounds that executive compensation disclosure is updated annually and that annual advisory input provides more timely shareholder feedback to inform compensation decisions. From a governance perspective, proponents of annual votes argue that they create continued accountability and quicker signaling to the Board on evolving shareholder views, particularly for a development-stage company experiencing frequent operational changes and milestone-driven decisions. Opponents argue that less frequent votes (e.g., triennial) can reduce administrative burden and allow compensation programs time to take effect before being judged; they also contend that overly frequent advisory votes can amplify short-term market noise. Given Orchestra’s pre-commercial stage, rapid program development and recent one-time awards and mid-year adjustments, management’s preference for annual feedback is consistent with seeking near-term shareholder input on evolving compensation practices. The vote is non-binding; the Board will consider the majority preference when setting future cadence. For institutional investors, the question reduces to balancing desire for frequent engagement and oversight against the potential for short-termism; the company’s recommendation for annual voting aligns with more active shareholder engagement norms and signals the Board’s willingness to receive recurrent feedback.